RRDA buys 10% of company for $4 million, valuing the company at $40 million, yet the market values the company at around $20 million. Even if you discount that purchase transaction by 20-25% the price of the stock s/b nearer to $.80 than the current $.49.
Opportunity or trap? I think the former. This stock is closely held and trades sporadically. Likely to go higher.
Don't forget earnings s/b announced next week.
Today's agreement values the company at $40M, double the existing market value....Hold onto your seats!
If you listen to cramer.......good luck.
Here's the real deal.......
Jason @JasonHolman5 4h4 hours ago
$TGTX TGR-1202 once daily oral PI3K delta inhib. establishing itself as the cornerstone(blockbuster potential)of a P/L w/increasing value.
thanks for the heads-up, my trading site showed something different. Can we expect a news release by monday morning, reflecting the huge bounce in the last minute of trading friday?
We reiterate our Buy rating, Focus Pick and $33 price target. We believe that
TG is positioning itself strongly with its lead candidate drugs, with the potential
to be integrated in the evolving standard of care for B-cell malignancies
Check the audio in last minute the CEO makes those comments...that's huge!
dougheuring @dougheuringaria 5m5 minutes ago
@LTbioinvestor $TGTX $MRK I expect positives moves also. $ONTY I missed congrats $CLVS $PBYI could be rough early & still 2 half days left 😃
max @LTbioinvestor 20m20 minutes ago
Major gapper tomorrow should be $ONTY ... minor gappers $CTIC $IMGN ... expecting a down open in $CLVS and $CALA ...
Don Shimoda @zDonShimoda 16m16 minutes ago
.@mcbio316 @AndyBiotech @danwardbio Of 13 pts who had already failed prior Herceptin Tx, ONT380+Herceptin achieved 1 CR, 3 PR, 5 SD $ONTY